Last10K.com

Inhibikase Therapeutics, Inc. (IKT) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Inhibikase Therapeutics, Inc.

CIK: 1750149 Ticker: IKT

View differences made from one year to another to evaluate Inhibikase Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inhibikase Therapeutics, Inc..

Continue

Assess how Inhibikase Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inhibikase Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: IKT
CIK: 1750149
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-016996
Submitted to the SEC: Wed Mar 31 2021 2:14:04 PM EST
Accepted by the SEC: Wed Mar 31 2021
Period: Thursday, December 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ikt/0001564590-21-016996.htm